3 enrolling by invitation. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Enrolling by invitation 3 |
| Phase 2 | 2 | Enrolling by invitation 2 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN) - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Enrolling by invitation | Truway Health, Inc. | 120 | 2025-10-23 | 2026-05-22 |
| Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis Light therapy - Progressive Multiple Sclerosis | Phase 1 | Enrolling by invitation | University of Texas Southwestern Medical Center | 20 | 2024-04-18 | 2025-12-31 |
| rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease rAAV-Olig001-ASPA, Levetiracetam, Prednisone - Canavan Disease | Phase 1 / Phase 2 | Enrolling by invitation | Myrtelle Inc. | 24 | 2021-04-01 | 2025-11-14 |
Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Canavan Disease (1) · Fatigue (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Sleepiness (1)
Nervous System Diseases (3) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Immune System Diseases (2) · Arthritis (1) · Autoimmune Diseases (1) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Central Nervous System Diseases (1) · Chronic Disease (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Disease Attributes (1)
Levetiracetam (1) · Naltrexone (1) · Phototherapy (1) · Prednisone (1)
Myrtelle Inc. (1) · Truway Health, Inc. (1) · University of Texas Southwestern Medical Center (1)
United States (3)
Gavin Solomon, President & CEO (1) · Peter Sguigna, MD (1) · Robert Lober, MD, PhD (1)